Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

13 novembre 2026 aggiornato da: Regeneron Pharmaceuticals

A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors

This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).

The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.

The study is looking at:

  • What side effects the study drug might cause
  • How well the study drug works
  • How much of the study drug is in the blood at different times
  • If the body reacts to the study drug, in a way that may cause the study drug to not work as well
  • What is the best dose of the study drug for treating previously treated, advanced solid tumors

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

320

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • North Carolina
      • Huntersville, North Carolina, Stati Uniti, 28078
        • Reclutamento
        • Carolina BioOncology Institute

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  1. Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
  2. Participants must not be candidates for curative surgery or radiation
  3. Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
  4. Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
  5. At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
  2. Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
  3. Has undergone major surgery within the 14 days prior to first administration of study intervention
  4. Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
  5. Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
  6. Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
  7. Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.

Note: Other protocol defined inclusion/ exclusion criteria apply

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Parte 1: aumento della dose

Administered per the protocol

Sperimentale: Parte 2: espansione della dose

Administered per the protocol

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Occurrence of dose-limiting toxicities (DLTs)
Lasso di tempo: Up to 21 days

Part 1 (Dose Escalation)

Up to 21 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of Serious Adverse Events (SAEs)
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of adverse event of special interests (AESIs)
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective response (investigator assessed) per RECIST 1.1
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Concentrations of ADC
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of total antibody
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of payload (ProDXd and DXd)
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Magnitude of ADA against REGN13089-M404-M2980
Lasso di tempo: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Duration of response per RECIST 1.1
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Time to response per RECIST 1.1
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Progression-free survival per RECIST 1.1
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Overall survival
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of TEAEs considered clinically significant
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Laboratory abnormalities considered clinically significant
Lasso di tempo: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 ottobre 2026

Completamento primario (Stimato)

10 marzo 2031

Completamento dello studio (Stimato)

10 marzo 2031

Date di iscrizione allo studio

Primo inviato

2 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

2 ottobre 2026

Primo Inserito (Effettivo)

7 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • R13089-ONC-25128

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Periodo di condivisione IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Criteri di accesso alla condivisione IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi